Document Detail


Late-term results of mitral valve replacement with St. Jude Medical mechanical valve prosthesis: Samsun experience.
MedLine Citation:
PMID:  17117754     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM OF THE STUDY: We have reported the short- and long-term results of mitral valve replacement in this article. METHODS: Mitral valve replacement was conducted in 276 patients in our clinic between January 1989 and March 2005. The youngest patient was 4 years old and the oldest patient was 74 years old. Mean age was 40.08 +/- 1.06 y. Of these patients, 41.3% were men and 58.7% were women. The reason for operation was mitral stenosis in 96 patients (34.78%), mitral insufficiency in 78 patients (29.26%) and mitral stenosis plus mitral insufficiency in 102 patients (36.96%). The aetiology of mitral valve lesions was acute rheumatic fever in 208 patients (75.36%). The aetiology of mitral valve lesions was degenerative in 37 patients (13.41%), ischaemic in 23 patients (8.33%) and congenital in 8 patients (2.9%). RESULTS: In the 5, 10 and 15-year periods, the actual survival rates were 87.64% +/- 2.02%, 83.35% +/- 2.38% and 68.19% +/- 5.63%, respectively. Thromboembolism was observed in 38 patients (13.77%). The rates of actual freedom from thromboembolism in the 5, 10 and 15-year periods were 93.08% +/- 1.53%, 88.48% +/- 1.99% and 81.06% +/- 3.43%, respectively. Of the 276 patients who had been observed for 15 years, 5 had (1.81%) valvular thrombosis. The rates of actual freedom from valvular thrombosis in the 5, 10 and 15-year periods were 98.89% +/- 0.64%, 98.04% +/- 0.87% and 98.04% +/- 0.87%, respectively. In the 15-year period, 23 patients (8.33%) had haemorrhage due to anti-coagulation. The rates of actual freedom from haemorrhage due to anti-coagulation in the 5, 10 and 15-year periods were 95.64% +/- 1.23%, 93.40% +/- 1.56% and 87.73% +/- 2.96%, respectively. Seven patients (2.54%) had prosthetic valvular endocarditis. The rates of actual freedom from endocarditis in the 5, 10 and 15-year periods were 98.51% +/- 0.74%, 97.60% +/- 0.97% and 97.01% +/- 1.13%, respectively. Nine patients (3.27%) were re-operated. The rates of actual freedom from re-operation in the 5, 10 and 15-year periods were 97.45% +/- 0.95%, 96.58% +/- 1.12% and 96.58% +/- 1.12%, respectively. CONCLUSIONS: St. Jude Medical mechanical valve prosthesis has been the valve of choice in our clinic owing to its excellent haemodynamic properties and low rates of complication.
Authors:
Mustafa Kemal Demirag; Hasan Tahsin Keceligil; Fersat Kolbakir
Related Documents :
17045674 - Sorin stentless pericardial valve versus carpentier-edwards perimount pericardial biopr...
2766524 - Determinants of survival in endomyocardial fibrosis.
8047494 - Spectrum of infective endocarditis during infancy and childhood: 20-year review.
7369664 - Have you checked all your breast implants?
15990954 - Glutathione synthetase deficiency.
6720864 - Predicting results in the orthoptic treatment of accommodative dysfunction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta cardiologica     Volume:  61     ISSN:  0001-5385     ISO Abbreviation:  Acta Cardiol     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-11-22     Completed Date:  2007-06-19     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  0370570     Medline TA:  Acta Cardiol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  537-44     Citation Subset:  IM    
Affiliation:
Ondokuz Mayis University Medical School, Dept. of Cardiovascular Surgery, Samsun, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Anticoagulants / therapeutic use
Child
Child, Preschool
Female
Heart Valve Prosthesis* / adverse effects
Heart Valve Prosthesis Implantation / instrumentation*
Humans
Male
Middle Aged
Mitral Valve Insufficiency / congenital,  etiology,  mortality,  surgery*
Mitral Valve Stenosis / congenital,  etiology,  mortality,  surgery*
Myocardial Ischemia / complications
Prosthesis Design
Reoperation
Rheumatic Heart Disease / complications
Survival Analysis
Time Factors
Treatment Outcome
Warfarin / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changes in escape rhythms several years after radiofrequency ablation of the atrioventricular juncti...
Next Document:  Role of myocardial bridging in the apical localization of stress cardiomyopathy.